{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:16:23Z","timestamp":1784805383903,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Increasing extracellular levels of serotonin (5-HT) in the brain ameliorates symptoms of depression and anxiety-related disorders, e.g., social phobias and post-traumatic stress disorder. Recent evidence from preclinical and clinical studies established the therapeutic\u00a0potential of drugs inducing the release of 5-HT via the 5-HT-transporter. Nevertheless, current 5-HT releasing compounds under clinical investigation carry the risk for abuse and deleterious side effects. Here, we demonstrate that<jats:italic>S<\/jats:italic>-enantiomers of certain ring-substituted cathinones show preference for the release of 5-HT ex vivo and in vivo, and exert 5-HT-associated effects in preclinical behavioral models. Importantly, the lead cathinone compounds (1) do not induce substantial dopamine release and (2) display reduced off-target activity at vesicular monoamine transporters and 5-HT<jats:sub>2B<\/jats:sub>-receptors, indicative of low abuse-liability and low potential for adverse events. Taken together, our findings identify these agents as lead\u00a0compounds that may prove useful for the treatment of disorders where elevation of 5-HT has proven beneficial.<\/jats:p>","DOI":"10.1038\/s41380-022-01843-w","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T16:02:51Z","timestamp":1668009771000},"page":"722-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Serotonin-releasing agents with reduced off-target effects"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9837-8973","authenticated-orcid":false,"given":"Felix P.","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0518-5791","authenticated-orcid":false,"given":"Marco","family":"Niello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cintulova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Sideromenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6016-1947","authenticated-orcid":false,"given":"Julian","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bulling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Kudlacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxia","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Holy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Katamish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Sandtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9166-9919","authenticated-orcid":false,"given":"Yulong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9584-6257","authenticated-orcid":false,"given":"Daniela D.","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2182-6966","authenticated-orcid":false,"given":"Randy D.","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko D.","family":"Mihovilovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-7444","authenticated-orcid":false,"given":"Harald H.","family":"Sitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"1843_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejphar.2014.10.031","volume":"753","author":"B Olivier","year":"2015","unstructured":"Olivier B. Serotonin: a never-ending story. Eur J Pharm. 2015;753:2\u201318.","journal-title":"Eur J Pharm"},{"key":"1843_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2009.03.044","volume":"1293","author":"JH Krystal","year":"2009","unstructured":"Krystal JH, Neumeister A. Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience. Brain Res. 2009;1293:13\u201323.","journal-title":"Brain Res"},{"key":"1843_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1124\/pr.108.000869","volume":"63","author":"AS Kristensen","year":"2011","unstructured":"Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ, et al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharm Rev. 2011;63:585\u2013640.","journal-title":"Pharm Rev"},{"key":"1843_CR4","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"JA Rush","year":"2006","unstructured":"Rush JA, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. STAR-D (2006; AjPsych) Tiered approach for depression. Am J Psychiatry. 2006;163:1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"1843_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1749-6632.1998.tb10192.x","volume":"861","author":"P Blier","year":"1998","unstructured":"Blier P, Pi\u00f1eyro G, El Mansari M, Bergeron R, De Montigny C. Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann N Y Acad Sci. 1998;861:204\u201316.","journal-title":"Ann N Y Acad Sci"},{"key":"1843_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.neuron.2009.12.003","volume":"65","author":"JW Richardson-Jones","year":"2010","unstructured":"Richardson-Jones JW, Craige CP, Guiard BP, Stephen A, Metzger KL, Kung HF, et al. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron. 2010;65:40\u201352.","journal-title":"Neuron."},{"key":"1843_CR7","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1021\/acschemneuro.7b00038","volume":"8","author":"AG Nackenoff","year":"2017","unstructured":"Nackenoff AG, Simmler LD, Baganz NL, Pehrson AL, S\u00e1nchez C, Blakely RD. Serotonin transporter-independent actions of the antidepressant vortioxetine as revealed using the SERT Met172 mouse. ACS Chem Neurosci. 2017;8:1092\u2013100.","journal-title":"ACS Chem Neurosci"},{"key":"1843_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tips.2014.11.006","volume":"36","author":"HH Sitte","year":"2015","unstructured":"Sitte HH, Freissmuth M. Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharm Sci. 2015;36:41\u201350.","journal-title":"Trends Pharm Sci"},{"key":"1843_CR9","doi-asserted-by":"crossref","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;7:1025\u201333","DOI":"10.1038\/s41591-021-01336-3"},{"key":"1843_CR10","doi-asserted-by":"crossref","unstructured":"Heifets BD, Salgado JS, Taylor MD, Hoerbelt P, Cardozo Pinto DF, Steinberg EE, et al. Distinct neural mechanisms for the prosocial and rewarding properties of MDMA. Sci Transl Med. 2019;11:eaaw6435.","DOI":"10.1126\/scitranslmed.aaw6435"},{"key":"1843_CR11","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1124\/jpet.104.080101","volume":"313","author":"S Wee","year":"2005","unstructured":"Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharm Exp Ther. 2005;313:848\u201354.","journal-title":"J Pharm Exp Ther"},{"key":"1843_CR12","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1111\/bph.13030","volume":"172","author":"JS Bonano","year":"2015","unstructured":"Bonano JS, Banks ML, Kolanos R, Sakloth F, Barnier ML, Glennon RA, et al. Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues. Br J Pharm. 2015;172:2433\u201344.","journal-title":"Br J Pharm"},{"key":"1843_CR13","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00213-015-4057-0","volume":"233","author":"CW Schindler","year":"2016","unstructured":"Schindler CW, Thorndike EB, Goldberg SR, Lehner KR, Cozzi NV, Brandt SD, et al. Reinforcing and neurochemical effects of the \u201cbath salts\u201d constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats. Psychopharmacology. 2016;233:1981\u201390.","journal-title":"Psychopharmacology"},{"key":"1843_CR14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/dmcn.14822","volume":"63","author":"M Gogou","year":"2021","unstructured":"Gogou M, Cross JH. Fenfluramine as antiseizure medication for epilepsy. Dev Med Child Neurol. 2021;63:899\u2013907.","journal-title":"Dev Med Child Neurol"},{"key":"1843_CR15","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2019","unstructured":"Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:2243\u201354.","journal-title":"Lancet."},{"key":"1843_CR16","doi-asserted-by":"crossref","unstructured":"Baumann MH, Walters HM, Niello M, Sitte HH. Neuropharmacology of Synthetic Cathinones. Handb Exp Pharmacol. 2018;252:113\u201342.","DOI":"10.1007\/164_2018_178"},{"key":"1843_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/bph.12951","volume":"172","author":"RA Gregg","year":"2015","unstructured":"Gregg RA, Baumann MH, Partilla JS, Bonano JS, Vouga A, Tallarida CS, et al. Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats. Br J Pharm. 2015;172:883\u201394.","journal-title":"Br J Pharm"},{"key":"1843_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.euroneuro.2015.12.010","volume":"26","author":"BA Hutsell","year":"2016","unstructured":"Hutsell BA, Baumann MH, Partilla JS, Banks ML, Vekariya R, Glennon RA, et al. Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats. Eur Neuropsychopharmacol. 2016;26:288\u201397.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1843_CR19","doi-asserted-by":"crossref","unstructured":"Mayer FP, Cintulova D, Pittrich DA, Wimmer L, Luethi D, Holy M, et al. Stereochemistry of phase-1 metabolites of mephedrone determines their effectiveness as releasers at the serotonin transporter. Neuropharmacology. 2019;148:199\u2013209.","DOI":"10.1016\/j.neuropharm.2018.12.032"},{"key":"1843_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2021.654061","volume":"12","author":"M Niello","year":"2021","unstructured":"Niello M, Cintulov\u00e1 D, Raithmayr P, Holy M, J\u00e4ntsch K, Colas C, et al. Effects of hydroxylated mephedrone metabolites on monoamine transporter activity in vitro. Front Pharm. 2021;12:1\u201313.","journal-title":"Front Pharm"},{"key":"1843_CR21","doi-asserted-by":"crossref","unstructured":"Angoa-P\u00e9rez M, Anneken JH, Kuhn DM. Neurotoxicology of synthetic cathinone analogs. Curr Top Behav Neurosci. 2017;32:209\u201330.","DOI":"10.1007\/7854_2016_21"},{"key":"1843_CR22","doi-asserted-by":"publisher","first-page":"172871","DOI":"10.1016\/j.pbb.2020.172871","volume":"191","author":"DE Muskiewicz","year":"2020","unstructured":"Muskiewicz DE, Resendiz-Gutierrez F, Issa O, Hall FS. Synthetic psychoactive cathinones: hypothermia and reduced lethality compared to methamphetamine and methylenedioxymethamphetamine. Pharm Biochem Behav. 2020;191:172871.","journal-title":"Pharm Biochem Behav"},{"key":"1843_CR23","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1021\/acschemneuro.7b00055","volume":"8","author":"AR Shalabi","year":"2017","unstructured":"Shalabi AR, Walther D, Baumann MH, Glennon RA. Deconstructed analogues of bupropion reveal structural requirements for transporter inhibition versus substrate-induced neurotransmitter release. ACS Chem Neurosci. 2017;8:1397\u2013403.","journal-title":"ACS Chem Neurosci"},{"key":"1843_CR24","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1038\/s41386-018-0209-3","volume":"43","author":"BM Gannon","year":"2018","unstructured":"Gannon BM, Baumann MH, Walther D, Jimenez-Morigosa C, Sulima A, Rice KC, et al. The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter. Neuropsychopharmacology. 2018;43:2399\u2013407.","journal-title":"Neuropsychopharmacology."},{"key":"1843_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejphar.2012.11.008","volume":"699","author":"NV Cozzi","year":"2013","unstructured":"Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulzer A, et al. Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharm. 2013;699:180\u20137.","journal-title":"Eur J Pharm"},{"key":"1843_CR26","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41593-021-00823-7","volume":"24","author":"J Wan","year":"2021","unstructured":"Wan J, Peng W, Li X, Qian T, Song K, Zeng J, et al. A genetically encoded sensor for measuring serotonin dynamics. Nat Neurosci. 2021;24:746\u201352.","journal-title":"Nat Neurosci"},{"key":"1843_CR27","doi-asserted-by":"crossref","unstructured":"Sun F, Zhou J, Dai B, Qian T, Zeng J, Li X, et al. Dopaminergic activity in vivo. Nat Methods. 2020;17:1156\u201366","DOI":"10.1038\/s41592-020-00981-9"},{"key":"1843_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/gbb.12482","volume":"18","author":"SN Reisinger","year":"2019","unstructured":"Reisinger SN, Kong E, Molz B, Humberg T, Sideromenos S, Cicvaric A, et al. Flotillin-1 interacts with the serotonin transporter and modulates chronic corticosterone response. Genes Brain Behav. 2019;18:1\u201311.","journal-title":"Genes Brain Behav"},{"key":"1843_CR29","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"E Erdfelder","year":"2009","unstructured":"Erdfelder E, Faul F, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149\u201360.","journal-title":"Behav Res Methods"},{"key":"1843_CR30","doi-asserted-by":"crossref","unstructured":"Mayer FP, Luf A, Nagy C, Holy M, Schmid R, Freissmuth M, et al. Application of a Combined Approach to Identify New Psychoactive Street Drugs and Decipher Their Mechanisms at Monoamine Transporters. Curr Top Behav Neurosci. 2017;32:333\u201350.","DOI":"10.1007\/7854_2016_63"},{"key":"1843_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuropharm.2018.06.018","volume":"138","author":"J Maier","year":"2018","unstructured":"Maier J, Mayer FP, Luethi D, Holy M, J\u00e4ntsch K, Reither H, et al. The psychostimulant (\u00b1)-cis-4,4\u2032-dimethylaminorex (4,4\u2032-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters. Neuropharmacology. 2018;138:282\u201391.","journal-title":"Neuropharmacology."},{"key":"1843_CR32","doi-asserted-by":"crossref","unstructured":"Khanppnavar B, Maier J, Herborg F, Gradisch R, Lazzarin E, Luethi D, et al. Structural basis of organic cation transporter-3 inhibition. BioRxiv. 2022:2022.07.14.499921.","DOI":"10.1101\/2022.07.14.499921"},{"key":"1843_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.tips.2020.04.006","volume":"41","author":"M Niello","year":"2020","unstructured":"Niello M, Gradisch R, Loland CJ, Stockner T, Sitte HH. Allosteric modulation of neurotransmitter transporters as a therapeutic strategy. Trends Pharm Sci. 2020;41:446\u201363.","journal-title":"Trends Pharm Sci"},{"key":"1843_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.neuropharm.2017.10.006","volume":"134","author":"FP Mayer","year":"2018","unstructured":"Mayer FP, Burchardt NV, Decker AM, Partilla JS, Li Y, McLaughlin G, et al. Fluorinated phenmetrazine \u201clegal highs\u201d act as substrates for high-affinity monoamine transporters of the SLC6 family. Neuropharmacology. 2018;134:149\u201357.","journal-title":"Neuropharmacology."},{"key":"1843_CR35","doi-asserted-by":"publisher","first-page":"104894","DOI":"10.1016\/j.neuint.2020.104894","volume":"142","author":"FP Mayer","year":"2021","unstructured":"Mayer FP, Iwamoto H, Hahn MK, Grumbar GJ, Stewart A, Li Y, et al. There\u2019s no place like home? Return to the home cage triggers dopamine release in the mouse nucleus accumbens. Neurochem Int. 2021;142:104894.","journal-title":"Neurochem Int"},{"key":"1843_CR36","doi-asserted-by":"publisher","first-page":"E4779","DOI":"10.1073\/pnas.1417294111","volume":"111","author":"MA Mergy","year":"2014","unstructured":"Mergy MA, Gowrishankar R, Gresch PJ, Gantz SC, Williams J, Davis GL, et al. The rare DAT coding variant Val559 perturbs da neuron function, changes behavior, and alters in vivo responses to psychostimulants. Proc Natl Acad Sci USA. 2014;111:E4779\u201388.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1843_CR37","doi-asserted-by":"publisher","first-page":"107615","DOI":"10.1016\/j.neuropharm.2019.04.021","volume":"161","author":"M Niello","year":"2019","unstructured":"Niello M, Cintulova D, Hellsberg E, J\u00e4ntsch K, Holy M, Ayatollahi LH, et al. para-Trifluoromethyl-methcathinone is an allosteric modulator of the serotonin transporter. Neuropharmacology. 2019;161:107615.","journal-title":"Neuropharmacology."},{"key":"1843_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.67996","volume":"10","author":"S Bhat","year":"2021","unstructured":"Bhat S, Niello M, Schicker K, Pifl C, Sitte HH, Freissmuth M, et al. Handling of intracellular k+ determines voltage dependence of plasmalemmal monoamine transporter function. Elife. 2021;10:1\u201323.","journal-title":"Elife."},{"key":"1843_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0014-2999(00)00639-7","volume":"406","author":"AE Fleckenstein","year":"2000","unstructured":"Fleckenstein AE, Gibb JW, Hanson GR. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharm. 2000;406:1\u201313.","journal-title":"Eur J Pharm"},{"key":"1843_CR40","doi-asserted-by":"crossref","unstructured":"Rothman RB, Baumann MH, Savage JE, Rauser L, Mcbride A, Hufeisen SJ, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102:2836\u201341.","DOI":"10.1161\/01.CIR.102.23.2836"},{"key":"1843_CR41","doi-asserted-by":"publisher","first-page":"6850","DOI":"10.1073\/pnas.110035297","volume":"97","author":"C Saunders","year":"2000","unstructured":"Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, et al. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA. 2000;97:6850\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1843_CR42","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1006\/bbrc.2002.6384","volume":"290","author":"LC Daws","year":"2002","unstructured":"Daws LC, Callaghan PD, Mor\u00f3n JA, Kahlig KM, Galli A, Mor\u00f3n JA, et al. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun. 2002;290:1545\u201350.","journal-title":"Biochem Biophys Res Commun"},{"key":"1843_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejphar.2009.12.010","volume":"629","author":"K Kittler","year":"2010","unstructured":"Kittler K, Lau T, Schloss P. Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. Eur J Pharm. 2010;629:63\u20137.","journal-title":"Eur J Pharm"},{"key":"1843_CR44","doi-asserted-by":"publisher","first-page":"E7138","DOI":"10.1073\/pnas.1511670112","volume":"112","author":"DS Wheeler","year":"2015","unstructured":"Wheeler DS, Underhill SM, Stolz DB, Murdoch GH, Thiels E, Romero G, et al. Amphetamine activates Rho GTPase signaling to mediate dopamine transporter internalization and acute behavioral effects of amphetamine. Proc Natl Acad Sci USA. 2015;112:E7138\u201347.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1843_CR45","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1124\/mol.61.2.436","volume":"61","author":"KY Little","year":"2002","unstructured":"Little KY, Elmer LW, Zhong H, Scheys JO, Zhang L. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol Pharm. 2002;61:436\u201345.","journal-title":"Mol Pharm"},{"key":"1843_CR46","doi-asserted-by":"publisher","unstructured":"Castagn\u00e9 V, Moser P, Roux S, Porsolt RD. Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci. 2011;Chapter 8:Unit 8.10A. https:\/\/doi.org\/10.1002\/0471142301.ns0810as55.","DOI":"10.1002\/0471142301.ns0810as55"},{"key":"1843_CR47","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/npp.2015.335","volume":"41","author":"AG Nackenoff","year":"2016","unstructured":"Nackenoff AG, Moussa-Tooks AB, McMeekin AM, Veenstra-VanderWeele J, Blakely RD. Essential contributions of serotonin transporter inhibition to the acute and chronic actions of fluoxetine and citalopram in the SERT Met172 mouse. Neuropsychopharmacology. 2016;41:1733\u201341.","journal-title":"Neuropsychopharmacology."},{"key":"1843_CR48","doi-asserted-by":"crossref","unstructured":"Mayer FP, Wimmer L, Dillon-Carter O, Partilla JSS, Burchardt NVV, Mihovilovic MDD, et al. Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters. Br J Pharmacol. 2016;173:2657\u201368.","DOI":"10.1111\/bph.13547"},{"key":"1843_CR49","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/hup.348","volume":"16","author":"ME Liechti","year":"2001","unstructured":"Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol. 2001;16:589\u201398.","journal-title":"Hum Psychopharmacol"},{"key":"1843_CR50","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0893-133X(99)00148-7","volume":"22","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, \"Ecstasy\") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 2000;22:513\u201321.","journal-title":"Neuropsychopharmacology"},{"key":"1843_CR51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2018.06.042","volume":"174","author":"F Sun","year":"2018","unstructured":"Sun F, Zeng J, Jing M, Zhou J, Feng J, Owen SF, et al. A genetically encoded fluorescent sensor enables rapid and specific detection of dopamine in flies, fish, and mice. Cell. 2018;174:481\u201396.e19.","journal-title":"Cell."},{"key":"1843_CR52","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neuropharm.2015.01.003","volume":"92","author":"KM Creehan","year":"2015","unstructured":"Creehan KM, Vandewater SA, Taffe MA. Intravenous self-administration of mephedrone, methylone and MDMA in female rats. Neuropharmacology. 2015;92:90\u20137.","journal-title":"Neuropharmacology."},{"key":"1843_CR53","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/adb.12398","volume":"22","author":"JD Nguyen","year":"2017","unstructured":"Nguyen JD, Grant Y, Creehan KM, Vandewater SA, Taffe MA. Escalation of intravenous self-administration of methylone and mephedrone under extended access conditions. Addict Biol. 2017;22:1160\u20138.","journal-title":"Addict Biol"},{"key":"1843_CR54","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1111\/bph.13043","volume":"172","author":"F Sakloth","year":"2015","unstructured":"Sakloth F, Kolanos R, Mosier PD, Bonano JS, Banks ML, Partilla JS, et al. Steric parameters, molecular modeling and hydropathic interaction analysis of the pharmacology of para-substituted methcathinone analogues. Br J Pharm. 2015;172:2210\u20138.","journal-title":"Br J Pharm"},{"key":"1843_CR55","doi-asserted-by":"crossref","unstructured":"Negus SS, Banks ML. Decoding the structure of abuse potential for new psychoactive substances: structure\u2014activity relationships for abuse-related effects of 4-substituted methcathinone analogs. Curr Top Behav Neurosci. 2017;32:119\u201331.","DOI":"10.1007\/7854_2016_18"},{"key":"1843_CR56","doi-asserted-by":"crossref","unstructured":"Luethi D. & Matthias EL. Designer drugs: mechanism of action and adverse effects. Arch Toxicol. 2020;94:1085\u2013133.","DOI":"10.1007\/s00204-020-02693-7"},{"key":"1843_CR57","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1471-4159.2011.07632.x","volume":"120","author":"M Angoa-P\u00e9rez","year":"2012","unstructured":"Angoa-P\u00e9rez M, Kane MJ, Francescutti DM, Sykes KE, Shah MM, Mohammed AM, et al. Mephedrone, an abused psychoactive component of \u2018bath salts\u2019 and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem. 2012;120:1097\u2013107.","journal-title":"J Neurochem"},{"key":"1843_CR58","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.neubiorev.2018.07.015","volume":"110","author":"AL Riley","year":"2020","unstructured":"Riley AL, Nelson KH, To P, L\u00f3pez-Arnau R, Xu P, Wang D, et al. Abuse potential and toxicity of the synthetic cathinones (i.e., \u201cBath salts\u201d). Neurosci Biobehav Rev. 2020;110:150\u201373.","journal-title":"Neurosci Biobehav Rev"},{"key":"1843_CR59","doi-asserted-by":"publisher","first-page":"172912","DOI":"10.1016\/j.pbb.2020.172912","volume":"192","author":"Y Chen","year":"2020","unstructured":"Chen Y, Tran HTN, Saber YH, Hall FS. High ambient temperature increases the toxicity and lethality of 3,4-methylenedioxymethamphetamine and methcathinone. Pharm Biochem Behav. 2020;192:172912.","journal-title":"Pharm Biochem Behav"},{"key":"1843_CR60","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/npp.2011.304","volume":"37","author":"MH Baumann","year":"2012","unstructured":"Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology. 2012;37:1192\u2013203.","journal-title":"Neuropsychopharmacology."},{"key":"1843_CR61","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0014-2999(99)00538-5","volume":"381","author":"NV Cozzi","year":"1999","unstructured":"Cozzi NV, Sievert MK, Shulgin AT, Jacob P, Ruoho AE. Inhibition of plasma membrane monoamine transporters by \u03b2- ketoamphetamines. Eur J Pharm. 1999;381:63\u20139.","journal-title":"Eur J Pharm"},{"key":"1843_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejphar.2015.03.004","volume":"755","author":"C Pifl","year":"2015","unstructured":"Pifl C, Reither H, Hornykiewicz O. The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter. Eur J Pharm. 2015;755:119\u201326.","journal-title":"Eur J Pharm"},{"key":"1843_CR63","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1124\/jpet.110.176271","volume":"337","author":"MH Baumann","year":"2011","unstructured":"Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB. In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharm Exp Ther. 2011;337:218\u201325.","journal-title":"J Pharm Exp Ther"},{"key":"1843_CR64","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-018-0416-4","volume":"560","author":"JJ Walsh","year":"2018","unstructured":"Walsh JJ, Christoffel DJ, Heifets BD, Ben-Dor GA, Selimbeyoglu A, Hung LW, et al. 5-HT release in nucleus accumbens rescues social deficits in mouse autism model. Nature. 2018;560:589\u201394.","journal-title":"Nature."},{"key":"1843_CR65","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","volume":"60","author":"M Berger","year":"2009","unstructured":"Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355\u201366.","journal-title":"Annu Rev Med"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01843-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01843-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01843-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T14:23:22Z","timestamp":1701354202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01843-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1038\/s41380-022-01843-w","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"11 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}